Breaking News Instant updates and real-time market news.

REGN

Regeneron

$307.43

1.565 (0.51%)

07:02
06/14/19
06/14
07:02
06/14/19
07:02

Regeneron announces 'positive early-stage data' for REGN1979

Regeneron announced positive early-stage data for REGN1979 in patients with relapsed or refractory B-cell non-Hodgkin lymphoma. The emerging data, which includes patients with R/R diffuse large B-cell lymphoma who had progressed after CAR-T therapy, will be presented tomorrow at the 24th Congress of the European Hematology Association. REGN1979 is an investigational bispecific monoclonal antibody and is designed to trigger tumor killing by binding to both a B-cell tumor protein and an immune system T-cell receptor. "We are very encouraged by the continued high response rates observed with REGN1979 in both relapsed or refractory diffuse large B-cell lymphoma and follicular lymphoma, cancers with typically poor outcomes," said Israel Lowy, M.D., Ph.D., Senior Vice President and Head of Clinical and Translational Sciences, Oncology at Regeneron. "In this trial, two patients who failed CAR-T therapy and received REGN1979 80 mg achieved complete responses; there is currently no approved therapy for patients who progress on CAR-Ts. Our potentially registrational Phase 2 program is initiating this month and will proactively evaluate active REGN1979 doses in indolent and aggressive non-Hodgkin lymphoma."

  • 14

    Jun

  • 26

    Jun

REGN Regeneron
$307.43

1.565 (0.51%)

05/20/19
LEHM
05/20/19
NO CHANGE
Target $315
LEHM
Underweight
Barclays still bearish on Regeneron despite 18% drop year-to-date
Barclays analyst Geoff Meacham says that despite the 18% decline of Regeneron Pharmaceuticals shares year-to-date, he remains bearish on the name with an Underweight rating and $315 price target. The analyst cites Eylea concentration risk and the near/long-term competitive threat in wet age-related macular degeneration. Pricing and/or share erosion in wet AMD from brolucizumab or DARPin could yield worse than consensus expectations, Meacham tells investors in a research note.
05/20/19
FBCO
05/20/19
INITIATION
Target $336
FBCO
Neutral
Regeneron initiated with a Neutral at Credit Suisse
Credit Suisse analyst Evan Seigerman started Regeneron Pharmaceuticals (REGN) with a Neutral rating and $336 price target. The analyst is concerned that Eylea could face "increasing headwinds" with the upcoming launch of Novartis' (NVS) brolucizumab. Further, he believes consensus estimates for the Sanofi (SNY) collaboration may be too high.
05/21/19
PIPR
05/21/19
NO CHANGE
Target $435
PIPR
Overweight
Piper, confident in Street-high Dupixent estimates, says buy Regeneron
Piper Jaffray analyst Christopher Raymond says he's increasingly confident in his Street-high Dupixent estimates following his firm's latest dermatologist survey. The survey indicated "steepening use trends" for Regeneron Pharmaceuticals' Dupixent and a "meaningful inflection" in use for atopic dermatitis, Raymond tells investors in a research note. Further, the feedback suggests that the new adolescent atopic dermatitis label is already driving "meaningful growth as well as continued acceleration," adds the analyst. He recommends buying shares of Regeneron at current levels and keeps an Overweight rating on the name with a $435 price target.
05/22/19
05/22/19
UPGRADE

Citi assumes coverage of large-cap biotech, upgrades Amgen and Gilead
Citi analyst Mohit Bansal assumed coverage of large-cap biotech stocks, assuming coverage with five Buy ratings -- Amgen (AMGN), Alexion Pharmaceuticals (ALXN), Vertex Pharmaceuticals (VRTX), Gilead Sciences (GILD), and BioMarin Pharmaceutical (BMRN) -- and two Neutral ratings -- Biogen (BIIB) and Regeneron Pharmaceuticals (REGN). Both Amgen and Gilead were upgraded to Buy from Neutral as part of the assumption of coverage. The analyst said he is "more optimistic" on the sector as a whole as he sees many biotechs going "back to basics" by investing in their internal pipelines and filling their pipelines with early stage assets. He suggests looking at large caps again, as many are returning to stability and growth. Bansal does not favor large M&A, suggesting discipline due to "realizing value with big M&As."

TODAY'S FREE FLY STORIES

XHR

Xenia Hotels

$20.41

-0.55 (-2.62%)

05:45
06/25/19
06/25
05:45
06/25/19
05:45
Initiation
Xenia Hotels initiated  »

Xenia Hotels initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ARCE

Arco Platform

$43.38

-2.35 (-5.14%)

05:41
06/25/19
06/25
05:41
06/25/19
05:41
Initiation
Arco Platform initiated  »

Arco Platform initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AGN

Allergan

$129.65

-1.32 (-1.01%)

, EOLS

Evolus

$13.69

0.13 (0.96%)

05:40
06/25/19
06/25
05:40
06/25/19
05:40
Recommendations
Allergan, Evolus analyst commentary  »

Allergan price target…

AGN

Allergan

$129.65

-1.32 (-1.01%)

EOLS

Evolus

$13.69

0.13 (0.96%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jun

QSR

Restaurant Brands

05:39
06/25/19
06/25
05:39
06/25/19
05:39
Initiation
Restaurant Brands initiated  »

Restaurant Brands…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SBUX

Starbucks

$83.65

-0.16 (-0.19%)

05:39
06/25/19
06/25
05:39
06/25/19
05:39
Initiation
Starbucks initiated  »

Starbucks initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jun

  • 09

    Jul

  • 09

    Jul

DPZ

Domino's Pizza

05:39
06/25/19
06/25
05:39
06/25/19
05:39
Initiation
Domino's Pizza initiated  »

Domino's Pizza…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Jul

  • 13

    Nov

SHAK

Shake Shack

05:39
06/25/19
06/25
05:39
06/25/19
05:39
Initiation
Shake Shack initiated  »

Shake Shack initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Jul

  • 09

    Jul

  • 14

    Aug

MCD

McDonald's

05:39
06/25/19
06/25
05:39
06/25/19
05:39
Initiation
McDonald's initiated  »

McDonald's initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jul

CMG

Chipotle

05:39
06/25/19
06/25
05:39
06/25/19
05:39
Initiation
Chipotle initiated  »

Chipotle initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jun

  • 27

    Jun

  • 09

    Jul

  • 09

    Jul

  • 23

    Jul

PZZA

Papa John's

$44.13

-0.25 (-0.56%)

05:38
06/25/19
06/25
05:38
06/25/19
05:38
Initiation
Papa John's initiated  »

Papa John's…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

WEN

Wendy's

$19.15

-0.22 (-1.14%)

05:38
06/25/19
06/25
05:38
06/25/19
05:38
Initiation
Wendy's initiated  »

Wendy's initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jun

  • 14

    Aug

  • 13

    Nov

YUM

Yum! Brands

$110.62

0.35 (0.32%)

05:38
06/25/19
06/25
05:38
06/25/19
05:38
Initiation
Yum! Brands initiated  »

Yum! Brands initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DNKN

Dunkin' Brands

$81.01

1.47 (1.85%)

05:38
06/25/19
06/25
05:38
06/25/19
05:38
Initiation
Dunkin' Brands initiated  »

Dunkin' Brands…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Jul

JACK

Jack in the Box

$82.83

-2.33 (-2.74%)

05:38
06/25/19
06/25
05:38
06/25/19
05:38
Initiation
Jack in the Box initiated  »

Jack in the Box initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jun

  • 27

    Jun

  • 08

    Aug

PYX

Pyxus

$13.42

-1.1 (-7.58%)

05:36
06/25/19
06/25
05:36
06/25/19
05:36
Initiation
Pyxus initiated  »

Pyxus initiated with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MSFT

Microsoft

$137.80

0.86 (0.63%)

, AMZN

Amazon.com

$1,913.43

3.01 (0.16%)

05:30
06/25/19
06/25
05:30
06/25/19
05:30
Recommendations
Microsoft, Amazon.com analyst commentary  »

Microsoft Azure likely…

MSFT

Microsoft

$137.80

0.86 (0.63%)

AMZN

Amazon.com

$1,913.43

3.01 (0.16%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jun

  • 09

    Jul

  • 10

    Jul

  • 06

    Aug

XONE

ExOne

$7.38

-0.21 (-2.77%)

, SIEGY

Siemens

$0.00

(0.00%)

05:28
06/25/19
06/25
05:28
06/25/19
05:28
Hot Stocks
ExOne announces partnership with Siemens »

ExOne (XONE) announced a…

XONE

ExOne

$7.38

-0.21 (-2.77%)

SIEGY

Siemens

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

SPTN

SpartanNash

$10.87

-0.05 (-0.46%)

05:23
06/25/19
06/25
05:23
06/25/19
05:23
Initiation
SpartanNash initiated  »

SpartanNash initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DERM

Dermira

$9.51

-0.405 (-4.08%)

05:23
06/25/19
06/25
05:23
06/25/19
05:23
Hot Stocks
Almirall exercises option with Dermira to license rights to lebrikizumab in EU »

Almirall and Dermira…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TLGHF

Telenet

$0.00

(0.00%)

05:15
06/25/19
06/25
05:15
06/25/19
05:15
Downgrade
Telenet rating change  »

Telenet downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DK

Delek US

$39.13

-0.635 (-1.60%)

05:14
06/25/19
06/25
05:14
06/25/19
05:14
Downgrade
Delek US rating change  »

Delek US downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CZR

Caesars

$11.43

1.44 (14.41%)

05:13
06/25/19
06/25
05:13
06/25/19
05:13
Downgrade
Caesars rating change  »

Caesars downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Jul

GRUB

GrubHub

$72.05

0.91 (1.28%)

05:13
06/25/19
06/25
05:13
06/25/19
05:13
Upgrade
GrubHub rating change  »

GrubHub upgraded to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jun

  • 09

    Jul

SITE

SiteOne Landscape

$66.97

-0.25 (-0.37%)

05:13
06/25/19
06/25
05:13
06/25/19
05:13
Upgrade
SiteOne Landscape rating change  »

SiteOne Landscape…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMZN

Amazon.com

$1,913.43

3.01 (0.16%)

05:13
06/25/19
06/25
05:13
06/25/19
05:13
Hot Stocks
Amazon announces 48 hour Prime Day July 15 & 16 »

Amazon said, "This…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jun

  • 10

    Jul

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.